Loading page content…
Loading page content…
Loading contract search results…
Loading contract details…
| Source: | Contracts Finder |
| Notice Type: | Award notice |
| Buyer: | Newcastle University |
| Main Category: | Services |
| Procurement Method: | Restricted procedure |
| Tender Status: | Closed |
Pipeline status
Not addedImports the contract into your BidWriter pipeline · Qualify before you commit to bid
Application Deadline
22 November 2022
Closed
Estimated Value
£30,000
Need help writing this bid?
Our specialists write winning tender responses. Free consultation, no obligation.
Book a free consultation →| Estimated Value (ex. VAT): |
| £30,000 |
| Release Date: | 20 January 2023 |
| Application Deadline: | 22 November 2022 |
| Contract Start Date: | 9 January 2023 |
| Contract End Date: | 30 April 2023 |
| Contract Duration: | 4 months |
| Procurement ID (OCID): | ocds-b5fd17-e7a3a34b-277b-4d1e-9068-3ffe382015d4 |
| Notice Reference: | 8f09ab8a-8ee1-461d-a966-12ca532a1495-607490 |
View Original Notice
Access the full notice on the official portal
Awarded to
| Award value: | £28,900 |
| Award decision date: | 22 December 2022 |
| Award status: | Active |
Three-dimensional (3D) bioprinting utilises printing techniques to combine cells, growth media and/or biomaterials to produce 3D bio-tissues, with the aim of imitating natural tissue characteristics. Fields in which 3D bioprinting could be used include tissue engineering, regenerative medicine, drug toxicology screening, clinical transplantation, high-throughput assays, and cancer research. The initial brief of the executive will be to: (1) Phase 1 - Provide a market assessment/evaluation and present a recommendation for launch and go-to-market strategy for company (2) Produce a viable 5 year business plan; (3) Obtain university approval for the venture; (4) a. Act for the company in the spin-out legal process and address all company formation matters; b. Obtain founder academics and Newcastle University (including the Head of Company Creation) approval for appointment as CEO. c. Provide to the appropriate university all matters necessary for Research England reporting requirements; (5) Secure (venture capital and other) funding